{
    "clinical_study": {
        "@rank": "104226", 
        "arm_group": {
            "arm_group_label": "MSB0010718C", 
            "arm_group_type": "Experimental"
        }, 
        "brief_summary": {
            "textblock": "This is a Phase 1, open-label, dose-escalation trial of MSB0010718C (antibody targeting\n      programmed death ligand 1 [anti PD-L1]) in Japanese subjects with metastatic or locally\n      advanced solid tumors, followed by a consecutive expansion part in Asian subjects with\n      gastric cancer."
        }, 
        "brief_title": "MSB0010718C in Metastatic or Locally Advanced Solid Tumors", 
        "completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Solid Tumors", 
        "condition_browse": {
            "mesh_term": "Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Signed written informed consent\n\n          -  Male or female subjects aged greater than or equal to 20 years\n\n          -  For dose escalation part: Histologically or cytologically proven metastatic or\n             locally advanced solid tumors, for which no standard therapy exists or standard\n             therapy has failed\n\n          -  For expansion part:\n\n               -  Availability of tumor in formalin fixed paraffin embedded tissue\n\n               -  With histologically or cytologically confirmed recurrent or refractory\n                  unresectable Stage IV gastric cancer (according to American Joint Committee on\n                  Cancer/Union Internationale Contre le Cancer [UICC]/International Association\n                  for Study of Lung Cancer Tumor Node Metastasis Classification of Malignant\n                  Tumors [TNM] Staging System 7th edition) and received first-line chemotherapy\n                  using fluoropyrimidine and platinum combination without disease progression\n\n               -  Presence of at least 1 measurable lesion according to RECIST version 1.1\n\n          -  Eastern Cooperative Oncology Group (ECOG)  performance status of 0 to 1 at the trial\n             entry and an estimated life expectancy of at least 3 months\n\n          -  Adequate hematological, hepatic and renal function as defined in the protocol\n\n          -  All subjects must agree to use effective means of contraception with their partner\n             from entry into the trial through 6 months after the last dose of MSB0010718C\n\n        Exclusion Criteria:\n\n          -  Concurrent treatment with a non-permitted drug\n\n          -  Prior therapy with any antibody/drug targeting T cell co-regulatory proteins (immune\n             checkpoints)\n\n          -  Concurrent anticancer treatment or concurrent systemic therapy with steroids or other\n             immunosuppressive agents, or use of any investigational drug within 30 days before\n             the start of trial treatment. Short-term administration of steroids (that is, for\n             allergic reactions or the management of immune-related adverse events [irAE]) is\n             allowed\n\n          -  Previous malignant disease within the last 5 years with the exception of adequately\n             treated non-melanoma skin cancer, in situ cancer, or other cancer\n\n          -  Pregnancy or lactation period\n\n          -  Known alcohol or drug abuse\n\n          -  Clinically significant (that is, active) cardiovascular disease\n\n          -  All other significant diseases (for example, inflammatory bowel disease), which, in\n             the opinion of the investigator, might impair the subject's tolerance of trial\n             treatment\n\n          -  Any psychiatric condition that would prohibit the understanding or rendering of\n             informed consent\n\n          -  Legal incapacity or limited legal capacity\n\n          -  Other protocol defined exclusion criteria could apply"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "20", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01943461", 
            "org_study_id": "EMR 100070-002"
        }, 
        "intervention": {
            "arm_group_label": "MSB0010718C", 
            "description": "MSB0010718C (anti PD-L1) will be administered in study location using a protocol-defined dose escalation scheme until confirmed complete response (CR), confirmed progression, unacceptable toxicity, or withdrawal from the trial or investigational medicinal product (IMP) occurs.", 
            "intervention_name": "MSB0010718C", 
            "intervention_type": "Drug", 
            "other_name": "anti PD-L1"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Solid Tumors", 
            "MSB0010718C", 
            "Phase 1"
        ], 
        "lastchanged_date": "April 29, 2014", 
        "location": {
            "contact": {
                "email": "service@merckgroup.com", 
                "phone": "+49-6151-72-5200"
            }, 
            "facility": {
                "address": {
                    "city": "Darmstadt", 
                    "country": "Germany"
                }, 
                "name": "Please contact the Merck KGaA Communication Center located in"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase I Trial to Investigate the Tolerability, Safety, Pharmacokinetics, Biological and Clinical Activity of MSB0010718C in Japanese Subjects With Metastatic or Locally Advanced Solid Tumors, With Expansion Part in Asian Subjects With Gastric Cancer", 
        "overall_contact": {
            "email": "service@merckgroup.com", 
            "last_name": "Merck KGaA Communication Center", 
            "phone": "+49 6151 72 5200"
        }, 
        "overall_official": {
            "affiliation": "Merck Serono Co., Ltd., Japan", 
            "last_name": "Medical Responsible", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Japan: Ministry of Health, Labor and Welfare", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Dose Limiting Toxicity", 
            "safety_issue": "Yes", 
            "time_frame": "Up to 3 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01943461"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetic parameters: AUC (0-t), AUC (0-infinity), \u03bbz, Cmax, Tmax, and t(1/2) of MSB0010718C", 
                "safety_issue": "No", 
                "time_frame": "Every 6-week up to Week 25"
            }, 
            {
                "measure": "Level of programmed death ligand 1 (PD-L1) tumor expression", 
                "safety_issue": "No", 
                "time_frame": "Every 6-week up to Week 25"
            }, 
            {
                "measure": "Evaluation of biologic response by receptor occupancy of MSB0010718C", 
                "safety_issue": "No", 
                "time_frame": "Days 1, 3, 15, 29, 43, and 85"
            }, 
            {
                "measure": "Immune-related Best Overall Response (irBOR) and Best Overall Response (BOR) according to modified Immune-related response criteria (irRC) and Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, respectively", 
                "safety_issue": "No", 
                "time_frame": "Time from inclusion in the trial until the date of first documented progression or discontinuation from the study due to any cause, up to 1 year after last treatment"
            }, 
            {
                "measure": "Immune-related Progression-Free Survival (irPFS) time and Progression-Free Survival (PFS) Time according to modified irRC and RECIST version 1.1, respectively", 
                "safety_issue": "No", 
                "time_frame": "Time from inclusion in the trial until first observation of progressive disease or death when death occurs within 12 weeks of the last tumor assessment or first administration of trial treatment (whichever is later) up to 1 year after last treatment"
            }, 
            {
                "measure": "Overall Survival Time", 
                "safety_issue": "No", 
                "time_frame": "Time from first treatment to death anticipated up to 1 year after last treatment"
            }, 
            {
                "measure": "Number of subjects with anti-MSB0010718C antibodies", 
                "safety_issue": "No", 
                "time_frame": "Every 6-week up to Week 25"
            }, 
            {
                "measure": "Number of subjects with Treatment-Emergent Adverse Events according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) Version 4.0", 
                "safety_issue": "Yes", 
                "time_frame": "Screening up to 28 days after last treatment"
            }
        ], 
        "source": "Merck KGaA", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck KGaA", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "September 2013", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}